Design and in vitro/in vivo evaluation of extended release matrix tablets of nateglinide

Pushkar R. Sharma, Shaila A. Lewis

Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal 576 104, Karnataka, India

Abstract

Aim: Nateglinide is a quick acting anti-diabetic medication whose potent activity lasts for a short duration. One of the dangerous side effects of nateglinide administration is rapid hypoglycemia, a condition that needs to be monitored carefully to prevent unnecessary fatalities. The aim of the study was to develop a longer lasting and slower releasing formulation of nateglinide that could be administered just once daily.

Methods: Matrix tablets of nateglinide were prepared in combination with the polymers hydroxypropylmethylcellulose (HPMC), eudragits, ethyl cellulose and polyethylene oxide and the formulated drug release patterns were evaluated using in vitro and in vivo studies.

Conclusion: Of the seventeen formulated matrix tablets tested, only one formulation labelled HA-2 that contained 15% HPMC K4M demonstrated release profile we had aimed for. Further, swelling studies and scanning electron microscopic analysis confirmed the drug release mechanism of HA-2. The optimized formulation HA-2 was found to be stable at accelerated storage conditions for 3 months with respect to drug content and physical appearance. Mathematical analysis of the release kinetics of HA-2 indicated a coupling of diffusion and erosion mechanisms. In-vitro release studies and pharmacokinetic in vivo studies of HA-2 in rabbits confirmed the sustained drug release profile we had aimed for.

Article Info

Article history:
Received 13 July 2013
Accepted 16 November 2013
Available online 11 December 2013

Keywords:
Hydroxypropylmethylcellulose
Matrix tablets
Nateglinide
Sustained release
3. Experimental methods

3.1. Preparation of nateglinide tablets

Tablets were prepared by direct compression. The investigated formulations are shown in Table 1. The respective powders (drug, polymers and excipients) were passed through 60# sieve. The powders were blended thoroughly using a mortar and pestle after which 500 mg of each mixture were weighed and manually fed into the die of a single punch tableting machine (Rimix tableting machine, Gujarat, India) equipped with 10.5 mm flat punches.

3.1.1. Conventional tablets for rabbits

Dosage for rabbits were calculated using following formula of Gosh.3,5 According to the dose calculated for rabbits (48.3 mg), the same formula was proportionately reduced and compressed into tablets using 2.5 mm flat punch.

Rabbit dose = 0.07 x human dose

where, human dose = 345 mg, rabbit weight = 2 kg and rabbit dose = 48.3 mg. The rabbit dose was found to be 1.5 times the observed value.

3.2. Evaluation of prepared tablets

3.2.1. Thickness and diameter

The prepared matrix tablets were evaluated for thickness, hardness, friability and drug content. Thicknesses of randomly selected tablets were determined using screw gauge. Hardness of the tablets was determined using Monsanto Hardness tester. Friability of tablets was determined using Roche Friabilator according to the official method I b.10 The values are expressed as the mean of three measurements (±SD).

3.2.2. Drug content

For determination of drug content, tablets were crushed and 100 mg of powder was dissolved in 100 ml of methanol. The filtrate further diluted with phosphate buffer (pH 6.8) was analyzed spectrophotometrically (UV-1601PC, Shimadzu, Japan) at 210 nm. Drug content was calculated using a standard curve generated using a calibration graph.

3.2.3. In vitro dissolution study

An in-vitro dissolution study of formulated matrix tablets was carried out in 900 ml 0.5% sodium lauryl sulphate (SLS) in 0.01 N HCl, followed by 900 ml of Phosphate buffer (pH 6.8) with type II paddle dissolution apparatus (Electrolab, TDL-08L, Mumbai, India) run at 50 rpm. The temperature of the medium was maintained at 37 ± 0.5 °C. Samples (5 ml) were withdrawn at predetermined intervals and read at 210 nm using a spectrophotometer.

3.2.4. Determination of swelling:eroding behaviour

The swelling-eroding behaviour of matrix tablets was determined using the method described by Al-Taani and Tashoush.11 One matrix tablet was weighed and placed in a dissolution apparatus. The swollen weights of tablets were calculated after placing the mixture in a vacuum oven at 40 °C for 48 h. The following formula was used for calculating % swelling

\[% Swelling = S/R \times 100\%
\]

where, S is the weight of the matrix after swelling and R is the weight of the eroded matrix.

3.2.5. Scanning electron microscopy

A SEM study of the optimized formulation was carried out confirming drug release mechanism. SEM photograph of the matrix tablets were taken at 0 h, 2 h, 12 h and 24 h of dissolution.

3.2.6. Stability

The tablets were kept under accelerated storage conditions 40 ± 2 °C and 75 ± 5% relative humidity according to ICH guidelines using a stability chamber (Thermolab, Mumbai) for a period of three months. The samples were withdrawn at predetermined time intervals and evaluated for drug content and physical parameters.

3.2.7. In vivo pharmacokinetic study

An in vivo pharmacokinetic study was conducted in accordance with the ethical guidelines for investigations in laboratory animals and approved by the Institutional Animal Ethics Committee (IAEC), Manipal University (MU) No.IAEC/KMC/21/2011. All procedures and care of the rabbits were in accordance with institutional guidelines for animal use in research. Twelve Rabbits (New Zealand, White) weighing 2.30 ± 0.12 kg (divided into two groups) were fasted overnight. Tablets were administered orally via gastric intubation. The first group received conventional tablet while the second group received optimized extended release tablet of nateglinide. Rabbits were held in rabbit restainers during blood sampling. Blood samples were collected from ear veins at predetermined intervals of

<table>
<thead>
<tr>
<th>Ingredients (mg/tablet)</th>
<th>Batch code</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nateglinide</strong></td>
<td>HA-1</td>
</tr>
<tr>
<td>345</td>
<td>345</td>
</tr>
<tr>
<td><strong>Lactose</strong></td>
<td>45</td>
</tr>
<tr>
<td>345</td>
<td>345</td>
</tr>
<tr>
<td><strong>HPMC K4M</strong></td>
<td>100</td>
</tr>
<tr>
<td><strong>HPMC K15M</strong></td>
<td>**</td>
</tr>
<tr>
<td><strong>HPMC K100M</strong></td>
<td>**</td>
</tr>
<tr>
<td><strong>Eudragit RS-100</strong></td>
<td>**</td>
</tr>
<tr>
<td><strong>Eudragit RL-100</strong></td>
<td>**</td>
</tr>
<tr>
<td><strong>Polyethylene oxide N 80 F</strong></td>
<td>**</td>
</tr>
<tr>
<td><strong>Talc</strong></td>
<td>5</td>
</tr>
<tr>
<td><strong>Magnesium stearate</strong></td>
<td>5</td>
</tr>
<tr>
<td><strong>Total Tab. Wt.</strong></td>
<td>500</td>
</tr>
</tbody>
</table>

** Indicates that ingredient is not included.
and thereby select a suitable polymer. HPMC K15M and HPMC nateglinide matrix tablets with different viscosity grades of HPMC 4.2. In vitro release pro
4.1. Evaluation of prepared tablets
4. Results
3.93% of nateglinide at the end of 0.5 h; at 24 h, 91.14, 78.22, 77.45, 60.40 and 78.43% of nateglinide was released. Since formulation HA-1, ES-1, EL-1, EC-1 and PO-1 released 7.31, 2.27, 0.50, 0.99 and 10% Eudragit RS-100, the percentage releases were 2.27, 4.24 and 4.99% respectively at the end of 0.5 h and 91.14, 96.62 and 97.92% at the end of 24 h. The release profile of HC-1 was retarded when compared to the formulations HA-1 and HB-1. Hence HA-1 and HB-2 were selected for the further studies.
 In formulations HA-1, HA-2 and HA-3 containing 20%, 15% and 10% HPMC K4M respectively, the percent releases were 7.31, 9.35 and 10.72% respectively at the end of 0.5 h and 91.14, 96.62 and 97.92% at the end of 24 h. In the cases of formulations HB-1, HB-2 and HB-3 containing 20%, 15% and 10% HPMC K15M respectively, the percentage releases were 3.93, 5.00 and 7.14% respectively at the end of 0.5 h and 85.28, 94.44 and 96.12% at the end of 24 h. Release studies illustrate incomplete drug release with formulation HA-1 and with formulation HA-3 it was observed that tablet integrity was lost resulting in complete release within12 h. Since release of nateglinide with 15% of HPMC K15M and 10% of HPMC K15M were lower compared with same concentrations of
3.2.9. Preparation of sample solutions
Rabbit plasma (100 μl) were pipetted into centrifugal tubes, 10 μl of IS (gliclazide) 500 μg/ml. was added and vortexed for 10 s. Then 100 μl methanol and acetonitrile 100 μl were added and vortexed for 30 s and centrifuged at 10000 rpm for 10 min at 4 °C. The supernatant layer (200 μl) was separated out, 100 μl of mobile phase was added make up the volume to 300 μl and then 50 μl was injected into HPLC system.
Pharmacokinetic analysis was performed by means of non-compartmental pharmacokinetic data analysis software PK Solutions 2.0 TM.

4. Results
4.1. Evaluation of prepared tablets
The tablets exhibited uniform thickness and hardness. The friability and drug content were also within the acceptable limits.

4.2. In vitro release profile
Release parameters of the tablet formulations are summarized in Fig. 1. Nateglinide release from the prepared tablets was slow, spanning a period of 24 h and rested on the grade of the controlled release polymer. The results of dissolution studies indicated that HA-1, ES-1, EL-1, EC-1 and PO-1 released 7.31, 2.27, 0.50, 0.99 and 3.93% of nateglinide at the end of 0.5 h; at 24 h, 91.14, 78.22, 77.45, 60.40 and 78.43% of nateglinide was released. Since formulation EC-1 containing ethyl cellulose showed incomplete release in the 24 h, further studies were discontinued.
A study was undertaken to determine the release profile of nateglinide matrix tablets with different viscosity grades of HPMC and thereby select a suitable polymer. HPMC K15M and HPMC K100M were selected for formulation and their release profile compared with HPMC K4M matrix tablets. Results indicate that the

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Release data of formulations.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formulation</td>
<td>% Release at 0.5 h</td>
</tr>
<tr>
<td>HA-1</td>
<td>7.31 ± 1.23</td>
</tr>
<tr>
<td>HB-1</td>
<td>3.39 ± 1.67</td>
</tr>
<tr>
<td>HC-1</td>
<td>1.02 ± 3.12</td>
</tr>
<tr>
<td>HA-2</td>
<td>9.35 ± 5.23</td>
</tr>
<tr>
<td>HA-3</td>
<td>10.72 ± 0.89</td>
</tr>
<tr>
<td>HB-2</td>
<td>5.00 ± 4.12</td>
</tr>
<tr>
<td>HB-3</td>
<td>7.14 ± 3.90</td>
</tr>
<tr>
<td>ES-1</td>
<td>2.27 ± 1.56</td>
</tr>
<tr>
<td>ES-2</td>
<td>4.24 ± 2.67</td>
</tr>
<tr>
<td>ES-3</td>
<td>4.99 ± 4.24</td>
</tr>
<tr>
<td>EL-1</td>
<td>0.50 ± 0.98</td>
</tr>
<tr>
<td>EL-2</td>
<td>2.53 ± 1.56</td>
</tr>
<tr>
<td>EL-3</td>
<td>2.77 ± 3.12</td>
</tr>
<tr>
<td>PO-1</td>
<td>3.93 ± 0.98</td>
</tr>
<tr>
<td>PO-2</td>
<td>6.32 ± 1.67</td>
</tr>
<tr>
<td>PO-3</td>
<td>7.56 ± 2.13</td>
</tr>
</tbody>
</table>

All values are expressed as Mean ± SE, n = 3. HA-1 (HPMC K4M 20%), HA-2 (HPMC K4M 15%), HA-3 (HPMC K4M 10%), HB-1 (HPMC K15M 20%), HB-2 (HPMC K15M 15%), HB-3 (HPMC K15M 10%), HC-1 (HPMC K100M 20%), ES-1 (Eudragit RS-100 20%), ES-2 (Eudragit RS-100 15%), ES-3 (Eudragit RS-100 10%), EL-1 (Eudragit RL-100 20%), EL-2 (Eudragit RL-100 15%), EL-3 (Eudragit RL-100 10%), PO-1 (polyethylene oxide 20%), PO-2 (polyethylene oxide 15%), PO-3 (polyethylene oxide 10%).

tablet formulations HA-1 (HPMC K4M), HB-1 (HPMC K15M) and HC-1 (HPMC K100M) released 7.31, 3.39 and 1.02% at the end of 0.5 h and 91.14, 85.28% and 64.75% of nateglinide at the end of 24 h. The release profile of HC-1 was retarded when compared to the formulations HA-1 and HB-1. Hence HA-1 and HB-2 were selected for the further studies.
In formulations HA-1, HA-2 and HA-3 containing 20%, 15% and 10% HPMC K4M respectively, the percentage release was 7.31, 9.35 and 10.72% respectively at the end of 0.5 h and 91.14, 96.62 and 97.92% at the end of 24 h. In the cases of formulations HB-1, HB-2 and HB-3 containing 20%, 15% and 10% HPMC K15M respectively, the percentage releases were 3.93, 5.00 and 7.14% respectively at the end of 0.5 h and 85.28, 94.44 and 96.12% at the end of 24 h. Release studies illustrate incomplete drug release with formulation HA-1 and with formulation HA-3 it was observed that tablet integrity was lost resulting in complete release within12 h.
Since release of nateglinide with 15% of HPMC K15M and 10% of HPMC K15M were lower compared with same concentrations of HPMC K4M, formulation HA-2 was selected for further studies.
For formulations ES-1, ES-2 and ES-3 containing 20%, 15% and 10% Eudragit RS-100, the percentage releases were 2.27, 4.24 and 4.99% respectively at the end of 0.5 h and 78.22, 90.39 and 97.06% at the end of 24 h (Table 2). For formulations EL-1, EL-2 and EL-3.

![Fig. 1. Release profile of formulations containing different polymers.](image1.png)

![Fig. 2. Percentage swelling of optimized formulation HA-2.](image2.png)
which contain 20%, 15% and 10% Eudragit RL 100, the percentage releases were 0.50, 2.53 and 2.77 respectively at the end of 0.5 h and 77.45, 92.53 and 94.34% at the end of 24 h (Table 2). These results indicate that lower percentage of Eudragit exhibit satisfactory release over a period of 24 h. Eudragits were not considered for further studies since inadequate amount of nateglinide was released at 0.5 h.

Matrix tablets with the polymer polyethylene oxide, PO-1, PO-2 and PO-3, exhibited better release with reduction in polymer concentration. Percentage release found with 20%, 15% and 10% polyoxyethylene were 78.43%, 82.39%, and 90.30% respectively; also, 10% polymer showed an initial release of 7.56% in 0.5 h (Table 2). The results indicate that 10% polyoxyethylene has potential for extended release formulation and further trials are needed to assess this potential. Formulation HA-2 (15% HPMC K4M) was selected for further studies.

4.3. In vivo pharmacokinetic study

The retention time of nateglinide and gliclazide was 11.5 and 7.55 min respectively (Fig. 5). The plasma concentrations of conventional nateglinide and extended release formulation over time are presented in Figs. 6 and 7 respectively. The pharmacokinetic parameters of conventional nateglinide and extended release formulation are presented in Table 3.

4.4. Stability studies

Accelerated stability studies conducted for the optimized batch of nateglinide extended release matrix tablets (HA-2) showed no change in drug appearance and assay after storage at 40 °C for 3 months. The drug content was 97% at the end of 90 days and appearance was unchanged indicating that the optimized formulation is fairly stable at accelerated storage condition.

5. Discussion

The results of dissolution studies indicate that release was influenced by the grade of control release polymer. Polymers ethylcellulose, HPMC K100M, eudragits and polyethylene oxide had a retarding effect compared to polymers HPMC K4M and HPMC K15M when used in same concentration. Hence further trials were not undertaken with these polymers. When polymer concentration
is high drug release rates are too low. Once there is sufficient polymer concentration in the matrix system a uniform barrier is formed. This barrier protects the drug from releasing immediately into the dissolution medium. Only formulation HA-2 followed the desired release profile up to 24 h.

The matrix tablets underwent both swelling and erosion at the same time after placement in the dissolution media. It has been reported that constant release can be obtained in such type of matrices.\(^\text{14}\) Constant release in such situations occurs because the increase in diffusion path length due to swelling is compensated for by continuous erosion of the matrix.\(^\text{15}\)

SEM further confirmed both diffusion and erosion mechanisms to be operative during drug release from the optimized formulation (HA-2). Initially, tablet matrix showed swelling with pore formation that is clearly visible from SEM image. At the end of 12 h, the matrix was intact and pores had formed through it. SEM images also show the formation of gel structure indicating swelling and pore formation on the tablet surface.

In case of Peppas model\(^\text{16}\); \(n\) values close to 0.64 indicate diffusion as the mode of release. In case of Higuchi \(R^2\), the value was close to unity indicating a linear response and clearly supporting the Peppas model. HA-2 showed \(R^2\) value close to unity when zero order model was applied which indicates good linearity and hence following zero order release. Korsmeyer’s plot showed good linearity with regression value of 0.9914 and slope 0.6562 indicating that diffusion is the dominant mechanism of drug release coupled with erosion.\(^\text{17}\)

In case of conventional tablet, nateglinide was detectable in blood within 30 min after its oral administration in rabbits. The absorption was rapid with conventional tablets as indicated by low \(t_{\text{max}}\) value (1.5 h) in comparison with HA-2 formulation which exhibited delayed absorption as demonstrated by high \(t_{\text{max}}\) (4 h) values. \(C_{\text{max}}\) value of conventional tablet was high compared with HA-2 (Table 3). In comparison, HA-2 formulation exhibited low elimination rate constant and high values of mean residential time (MRT). The low area under the curve (AUC) was observed with conventional tablets whereas the extended release formulation showed high AUC values indicating increased bioavailability of the drug in the matrix tablet.

The results of the \textit{in vivo} bioavailability test indicate that drug release from matrix tablet is controlled thereby providing prolonged drug delivery.

### 6. Conclusion

Extended release matrix tablets of nateglinide were prepared by direct compression. Various polymers in varying concentrations
were developed and evaluated. The formulation containing 15% HPMC K15M (HA-2) followed the desired release profile and was therefore selected for further studies. SEM studies revealed initial swelling and intact structure of the formulated tablets. Erosion and diffusion mechanisms were responsible for the sustained release of nateglinide from formulated matrix tablet. In vivo pharmacokinetic studies in rabbits confirmed the prolonged release by showing increase in bioavailability for matrix tablet compared to conventional tablet. The formulation (HA-2) was found stable under accelerated conditions for 3 months with respect to physical characteristics and drug content. However clinical studies and extensive stability studies at different conditions are required to confirm these results.

Conflicts of interest

All authors have none to declare.

Acknowledgements

The authors acknowledge the support of Manipal University in carrying out the research work.

References